Pfizer CEO Says There Are No Delays In Vaccine Production And Shipment In The US

Pfizer CEO Says There Are No Delays In Vaccine Production And Shipment In The US
Pfizer CEO Says There Are No Delays In Vaccine Production And Shipment In The US

Video: Pfizer CEO Says There Are No Delays In Vaccine Production And Shipment In The US

Отличия серверных жестких дисков от десктопных
Video: Pfizer CEO Albert Bourla on Covid-19 vaccine manufacturing outlook 2023, February
Anonim

NEW YORK, December 17. / TASS /. The American company Pfizer does not face any difficulties in the production and transportation of the vaccine against the new coronavirus in the United States, developed in conjunction with the German BioNTech. Pfizer CEO Albert Burla said this on Twitter on Thursday.

“Pfizer has no difficulty in producing our COVID-19 vaccine or any delays in shipping it,” he said. The company this week shipped 2.9 million doses of the drug ordered by the US federal government and shipped them to pre-determined locations. "We have millions of doses in stock. We have not yet received instructions on what to do with these doses," added the head of the company.

US Health and Human Services Secretary Alex Azar said at a press briefing on Wednesday that Pfizer had informed US authorities about the possibility of difficulties in the production of a vaccine against the coronavirus. The minister confirmed that the federal government is in talks with the company to purchase additional doses of the drug.

On Wednesday, The New York Times, citing sources, reported that the US administration is in talks with Pfizer to supply it with additional raw materials, which would allow the company to produce tens of millions of additional doses of vaccines for American citizens over the next six months. The publication recalled that in the summer, Pfizer agreed to supply the United States with 100 million doses of vaccine by the end of March 2021. The administration later requested additional doses of the drug from the company. Pfizer refused, saying that all doses planned for production in the near future had already been purchased by other countries. However, recently, the newspaper noted, the company announced the possibility of increasing vaccine production, if the administration will assist Pfizer in obtaining the necessary raw materials on a priority basis.

On December 11, the Food and Drug Administration of the US Department of Health and Human Services approved the vaccine developed by Pfizer and BioNTech for a specific time frame and in response to emergencies. The effectiveness of the drug is 95% after the second dose, one person needs two doses. The vaccine must be stored at a temperature of minus 75-80 degrees Celsius (after thawing, it is permissible to store ampoules at a temperature of 2-8 degrees for no more than five days). Use of the drug began in the US on Monday.

Popular by topic